fbpx
  • Home
  • Study Details
Not currently enrolling

Dupilumab Eosinophilic Gastritis Study (DEGAS)

To see if a drug administered via injection (dupilumab) is safe and effective at reducing eosinophilic inflammation in the stomach of participants with eosinophilic gastritis (EG)/ eosinophilic gastroenteritis (EGE).

Age & Gender

  • 12 years ~ 70 years
  • Male, Female, Gender Inclusive

Contact the Team

Location

Thank you for your interest, but this study is not currently enrolling.

United States (Nationwide)

Additional Study Information

Principal Investigator

Evan Dellon
Medicine-Gastroenterology

Study Type

Clinical or Medical
Interventional

Study Topics

Stomach, Digestion and Gut Health

IRB Number

21-0025

ClinicalTrials.gov

NCT03678545

Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research